The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Com
about
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.
P2860
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Com
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
The European Medicines Agency ...... ientific Assessment of the Com
@ast
The European Medicines Agency ...... ientific Assessment of the Com
@en
type
label
The European Medicines Agency ...... ientific Assessment of the Com
@ast
The European Medicines Agency ...... ientific Assessment of the Com
@en
prefLabel
The European Medicines Agency ...... ientific Assessment of the Com
@ast
The European Medicines Agency ...... ientific Assessment of the Com
@en
P2093
P2860
P1433
P1476
The European Medicines Agency ...... ientific Assessment of the Com
@en
P2093
Christian Gisselbrecht
Edward Laane
Francesco Pignatti
Iordanis Gravanis
Jan Mueller-Berghaus
Kyriaki Tzogani
Lothar Bergmann
Paula van Hennik
Petra Schmitt
Pieter de Graeff
P2860
P304
P356
10.1634/THEONCOLOGIST.2015-0276
P577
2015-11-30T00:00:00Z